Evidence-Based Benefits of
Regenerative Biologics
Explore the peer-reviewed research behind OmniGenix's portfolio of pre-COVID MSC exosomes, Wharton's Jelly-derived stem cells, and therapeutic peptides. Every claim below is supported by published scientific literature.
Important Notice: The information on this page is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements below reflect findings from published peer-reviewed research and have not been evaluated by the Food and Drug Administration. OmniGenix products are not drugs and are not intended as substitutes for professional medical advice. Always consult a qualified healthcare provider before beginning any new treatment protocol.
The Emerging Science of Exosome Therapy
Exosomes are nano-scale extracellular vesicles (30-150 nm) secreted by mesenchymal stem cells. They carry bioactive cargo - including proteins, lipids, microRNAs, and mRNAs - that facilitate intercellular communication and may influence cellular behavior in recipient tissues. A growing body of peer-reviewed literature suggests they hold significant promise across multiple therapeutic domains.
Tissue Regeneration & Wound Healing
In preclinical models, MSC-derived exosomes have been shown to promote wound healing, stimulate bone regeneration, and support cartilage repair by transferring regenerative proteins, mRNAs, and microRNAs to recipient cells. Research indicates they may reprogram cellular behavior to favor tissue restoration over scar formation.
Inflammation Modulation
Published research suggests that MSC exosomes possess immunomodulatory properties, potentially helping to modulate inflammatory pathways. In rat osteoarthritis models, human umbilical cord MSC-derived exosomes were observed to reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inhibit cartilage-degrading enzymes while promoting collagen II expression.
Hair Regeneration & Scalp Health
A 2024 systematic review of clinical studies found that MSC-derived exosome treatments were associated with significant improvements in hair density - increases of up to 35 hairs/cm² in treated areas - with 80% of participants reporting noticeable improvement. The exosomes appeared to increase dermal papilla cell proliferation and promote angiogenesis to hair follicles.
Placental MSC Exosome Anti-Inflammatory Pathways
Research published in the European Journal of Pharmacology demonstrated that human placental MSC-derived exosomes exhibit anti-inflammatory effects by regulating TLR4-mediated NF-κB/MAPK and PI3K signaling pathways. Additionally, a randomized controlled trial found that placental MSC-derived small extracellular vesicles were associated with significantly reduced mortality rates (19% vs. 54% in controls).
Safety Advantages Over Cell-Based Therapies
Compared to whole stem cell therapies, exosomes offer several theoretical safety advantages documented in the literature: they are non-immunogenic, carry no risk of abnormal differentiation or tumorigenesis, present no infusion-related toxicity, and are easier to store and standardize. Multiple review articles describe them as a promising "cell-free" alternative.
Cardiac & Systemic Signaling Support
A 2025 review in Molecular Biomedicine highlighted the emerging role of MSC exosomes in cardiac regeneration, noting their potential to promote angiogenesis, reduce apoptosis, and modulate fibrosis. Researchers describe exosomes as a promising new era in cell-free regenerative strategies for cardiovascular conditions.
Why Pre-COVID MSC Sourcing Matters
OmniGenix exosomes are derived exclusively from a pre-COVID single-donor placental MSC master cell line. This means the biological material was established before the emergence of SARS-CoV-2, ensuring it is entirely free of spike proteins and related contaminants.
This pre-COVID sourcing provides an additional layer of confidence in product purity that post-pandemic cell lines cannot guarantee. Combined with our FDA-approved cell line origin and serum-free, chemically defined culture media, OmniGenix exosomes represent a standard of biological purity that sets us apart in the industry.
MSC-derived exosomes
registered on ClinicalTrials.gov
WJ-MSC in knee OA
purity standard
The Science Behind Mesenchymal Stem Cell Therapy
Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) are sourced from the umbilical cord - an ethically obtained, non-controversial tissue collected following full-term, healthy births. Peer-reviewed literature highlights several characteristics that make WJ-MSCs a compelling platform for regenerative medicine.
Joint & Cartilage Support
A prospective clinical study found that intra-articular injection of Wharton's Jelly-derived MSCs in patients with knee osteoarthritis resulted in significant pain reduction, improved functional outcomes, and increased cartilage thickness on MRI at 1-year follow-up. No serious adverse effects were reported.
Powerful Paracrine Activity
A 2023 concise review published in Frontiers found that most of WJ-MSC therapeutic potential is attributed to their paracrine activity - their ability to modulate the microenvironment by releasing a complex mixture of growth factors, cytokines, and exosomes collectively known as the "secretome."
Immunomodulatory Properties
Published research documents that WJ-MSCs possess unique immunomodulatory properties affecting both innate and adaptive immune responses. Multiple studies have documented beneficial outcomes when WJ-MSCs were administered to patients with graft-versus-host disease refractory to standard treatments, even when not fully HLA-identical.
Superior Proliferative Capacity
Research indicates that WJ-MSCs exhibit excellent proliferative potential and faster growth rates compared to adult MSCs from bone marrow or adipose tissue. They also retain multipotency for more passages in vitro, and their collection at the time of delivery is non-invasive and free from the side effects associated with bone marrow aspiration.
Multipotent Differentiation
Characterized WJ-MSCs express standard mesenchymal markers (CD73+, CD90+, CD105+) and have demonstrated the capacity to differentiate into osteogenic, chondrogenic, adipogenic, and neurogenic lineages in laboratory settings - making them a versatile platform for diverse regenerative applications.
Active Clinical Trials in Osteoarthritis
As of late 2023, seven clinical trials are registered on ClinicalTrials.gov studying the effects of Wharton's Jelly and associated MSCs for treatment of knee osteoarthritis. A 2024 review in the British Medical Bulletin highlighted that UC-derived Wharton's Jelly contains regenerative factors including growth factors, cytokines, hyaluronic acid, and extracellular vesicles.
Research-Backed Peptide Science
Peptides are short chains of amino acids that serve as signaling molecules in the body. The OmniGenix peptide catalog includes compounds studied across tissue repair, metabolic optimization, cognitive function, immune support, and longevity. Below are highlights from the published literature.
BPC-157: Tissue Repair Peptide
A 2025 systematic review of 36 studies (1993-2024) found that BPC-157 promotes healing by boosting growth factors and reducing inflammation, improving outcomes in muscle, tendon, ligament, and bone injury models. The peptide modulates angiogenesis through VEGFR2 activity and the Akt-eNOS pathway, enhancing new capillary formation essential for tissue repair.
TB-500 (Thymosin Beta-4): Wound Healing
Research published in the Journal of Investigative Dermatology showed that thymosin beta-4 application increased re-epithelialization by up to 61% over controls at 7 days post-wounding. In Phase 2 clinical trials for stasis and pressure ulcers, it was associated with accelerated healing by nearly a month in responding patients. It also appeared to reduce scar formation by decreasing myofibroblast presence.
Semaglutide: GLP-1 Receptor Agonist
Clinical trials published in the New England Journal of Medicine demonstrated that semaglutide was associated with a placebo-corrected weight loss of approximately 12%. After 1 year, participants experienced a mean weight loss of 14.6 kg (-14.1%). Research also suggests potential benefits beyond weight management, including cardiovascular health and metabolic optimization.
Tirzepatide: Dual GIP/GLP-1 Agonist
A landmark NEJM study found that tirzepatide was superior to semaglutide for both body weight reduction and waist circumference at 72 weeks, with participants experiencing an average of 17.2 kg (-16.5%) weight loss. A meta-analysis confirmed tirzepatide produced significantly greater weight loss regardless of study design.
GHK-Cu: Copper Peptide
A 2018 review in the International Journal of Molecular Sciences reported that GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis, increases blood vessel and nerve outgrowth, and possesses anti-inflammatory and DNA repair actions. Its ability to improve tissue repair has been demonstrated in skin, lung, bone, liver, and stomach lining models.
Epitalon: Telomere Support
Research indicates that Epitalon (Ala-Glu-Asp-Gly) - a synthetic tetrapeptide derived from the pineal gland - has been shown to increase telomere length in human cell lines through telomerase upregulation. Studies suggest potential roles in circadian rhythm regulation and neuroendocrine function supporting healthy aging processes.
Thymosin Alpha-1: Immune Modulation
A comprehensive 2020 review documented that thymosin alpha-1 - a naturally occurring thymic peptide - has been utilized in treating immunocompromised states, malignancies, and as a vaccine response enhancer. Studies describe its role in augmenting immune response in deficiencies, psoriatic arthritis, aging, and reducing chemotherapy-induced toxicity.
Ready to Explore Regenerative Solutions?
Our clinical team can help you navigate the evidence and identify the right protocols for your practice and patient population.
Contact Us
Call Us
+1 (888) 554-4777
Email Us
support@omnigenix.com
Working Hours (PST)
Monday ————- 7:00 – 5:00
Tuesday ————- 7:00 – 5:00
Wednesday ——— 7:00 – 5:00
Thursday ———— 7:00 – 5:00
Friday —————- 7:00 – 5:00
Questions?
We would be happy to answer any questions you might have about our MSC exosome products. You may call, email, or schedule a product consultation appointment at your convenience.